Cancer Genetics, Inc. (CGIX) Analysts See $-0.16 EPS

October 14, 2018 - By Marguerite Chambers

Cancer Genetics, Inc. (NASDAQ:CGIX) LogoInvestors sentiment decreased to 1 in 2018 Q2. Its down 0.11, from 1.11 in 2018Q1. It worsened, as 5 investors sold Cancer Genetics, Inc. shares while 3 reduced holdings. 4 funds opened positions while 4 raised stakes. 2.36 million shares or 12.47% less from 2.70 million shares in 2018Q1 were reported.
Credit Suisse Ag stated it has 10,090 shares. Moreover, Diker Lc has 0.02% invested in Cancer Genetics, Inc. (NASDAQ:CGIX). Vanguard Inc, a Pennsylvania-based fund reported 242,280 shares. Perkins Cap invested in 0.64% or 1.00M shares. Thompson Davis Commerce stated it has 500 shares. Granahan Invest Management Ma reported 276,417 shares. Morgan Stanley reported 0% of its portfolio in Cancer Genetics, Inc. (NASDAQ:CGIX). Panagora Asset Mgmt has invested 0% in Cancer Genetics, Inc. (NASDAQ:CGIX). Sei Invests reported 5,000 shares. Barclays Public Ltd Com owns 454 shares. Court Place Advsr Lc holds 10,000 shares or 0% of its portfolio. Northern Corp reported 32,576 shares. Blackrock Inc holds 5,433 shares or 0% of its portfolio. Retail Bank Of America Corp De owns 625 shares. Wells Fargo And Com Mn holds 0% or 1,800 shares.

Analysts expect Cancer Genetics, Inc. (NASDAQ:CGIX) to report $-0.16 EPS on November, 8.They anticipate $0.00 EPS change or 0.00 % from last quarter’s $-0.16 EPS. After having $-0.13 EPS previously, Cancer Genetics, Inc.’s analysts see 23.08 % EPS growth. The stock decreased 1.29% or $0.011 during the last trading session, reaching $0.839. About 93,366 shares traded. Cancer Genetics, Inc. (NASDAQ:CGIX) has declined 69.23% since October 14, 2017 and is downtrending. It has underperformed by 84.85% the S&P500.

Cancer Genetics, Inc. develops, commercializes, and provides molecular and biomarker tests and services in the United States, India, and China. The company has market cap of $23.28 million. The Company’s tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. It currently has negative earnings. The company's clinical services provide information on diagnosis, prognosis, and predicting treatment outcomes of cancers to guide patient management.

More notable recent Cancer Genetics, Inc. (NASDAQ:CGIX) news were published by: Globenewswire.com which released: “Cancer Genetics and NovellusDx Sign Definitive Agreement to Merge” on September 18, 2018, also Globenewswire.com with their article: “Cancer Genetics Enters Supply Agreement with Agilent Technologies” published on September 25, 2018, Globenewswire.com published: “Cancer Genetics and Cellaria Partner on Precision Medicine Tools” on October 08, 2018. More interesting news about Cancer Genetics, Inc. (NASDAQ:CGIX) were released by: Streetinsider.com and their article: “After-Hours Stock Movers 09/25: (VSTM) (CGIX) (AIR) Higher; (DGLY) (ESNC) (NKE) Lower (more…)” published on September 25, 2018 as well as Investingnews.com‘s news article titled: “VIDEO — Life Science Update September 2018” with publication date: October 03, 2018.

Cancer Genetics, Inc. (NASDAQ:CGIX) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>